Immunomodulatory Agents in Follicular Lymphoma

被引：5

作者：

Ysebaert, Loic ^{[1
]}

Morschhauser, Franck ^{[2
]}

机构：

[1] IUC Toulouse Oncopole, Inst Univ Canc Toulouse Oncopole, INSERM, Serv Hematol,UMR1037,Ctr Canc Res Toulouse CRCT, 1 Ave Irene Joliot Curie, F-31059 Toulouse, France

[2] Univ Lille, CHU Lille, ULR 7365, GRITA Grp Rech Formes Injectables & Technol Assoc, Lille, France

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2020年 / 34卷 / 04期

关键词：

Chemo-free approaches; Follicular lymphoma; Immunomodulatory agents; Monoclonal antibodies; Tumor immune microenvironment; PHASE-II TRIAL; CELL; LENALIDOMIDE; RITUXIMAB; BLOCKADE; MICROENVIRONMENT; OBINUTUZUMAB; INHIBITION; EXPRESSION; SURVIVAL;

D O I：

10.1016/j.hoc.2020.02.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

New treatment strategies in follicular lymphoma (FL) are driven by a deeper understanding of microenvironmental cues supporting lymphomagenesis, chemoresistance, and immuno-escape. These immune-mediated signaling pathways contribute to initial learnings and clinical successes with lenalidomide, the first, oral, non-chemotherapeutic immunomodulatory drug, combined with anti-CD20 antibodies. This combination of lenalidomide with rituximab showed similar efficacy to chemoimmunotherapy (CIT) in first-line patients requiring therapy, and is approved in relapsed/refractory FL. We review the biology supporting the rationale for adequate inhibitory receptor/ligand pathways targeting the tissue immune microenvironment of FL cells, and potential immunomodulating combinations to replace CIT in the near future.

引用

页码：715 / +

页数：14

共 65 条

[21] Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia [J].

Fiorcari, Stefania ;

Martinelli, Silvia ;

Bulgarelli, Jenny ;

Audrito, Valentina ;

Zucchini, Patrizia ;

Colaci, Elisabetta ;

Potenza, Leonardo ;

Narni, Franco ;

Luppi, Mario ;

Deaglio, Silvia ;

Marasca, Roberto ;

Maffei, Rossana .

HAEMATOLOGICA, 2015, 100 (02) :253-262

[22] Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial [J].

Fowler, Nathan H. ;

Davis, R. Eric ;

Rawal, Seema ;

Nastoupil, Loretta ;

Hagemeister, Fredrick B. ;

McLaughlin, Peter ;

Kwak, Larry W. ;

Romaguera, Jorge E. ;

Fanale, Michelle A. ;

Fayad, Luis E. ;

Westin, Jason R. ;

Shah, Jatin ;

Orlowski, Robert Z. ;

Wang, Michael ;

Turturro, Francesco ;

Oki, Yasuhiro ;

Claret, Linda C. ;

Feng, Lei ;

Baladandayuthapani, Veerabhadran ;

Muzzafar, Tariq ;

Tsai, Kenneth Y. ;

Samaniego, Felipe ;

Neelapu, Sattva S. .

LANCET ONCOLOGY, 2014, 15 (12) :1311-1318

[23] PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas [J].

Goodman, Aaron ;

Patel, Sandip P. ;

Kurzrock, Razelle .

NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (04) :203-220

[24] Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma [J].

Gribben, John G. ;

Fowler, Nathan ;

Morschhauser, Franck .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2803-U127

[25]

Haebe S, 2019, AM SOC HEM M 2019 OR

[26] Hallmarks of Cancer: The Next Generation [J].

Hanahan, Douglas ;

Weinberg, Robert A. .

CELL, 2011, 144 (05) :646-674

[27] Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation [J].

Hatterer, Eric ;

Barba, Leticia ;

Noraz, Nelly ;

Daubeuf, Bruno ;

Aubry-Lachainaye, Jean-Pierre ;

von der Weid, Benoit ;

Richard, Francoise ;

Kosco-Vilbois, Marie ;

Ferlin, Walter ;

Shang, Limin ;

Buatois, Vanessa .

MABS, 2019, 11 (02) :322-334

[28] The emerging role of immune checkpoint inhibition in malignant lymphoma [J].

Hude, Ida ;

Sasse, Stephanie ;

Engert, Andreas ;

Broeckelmann, Paul J. .

HAEMATOLOGICA, 2017, 102 (01) :30-42

[29] From genetics to the clinic: a translational perspective on follicular lymphoma [J].

Huet, Sarah ;

Sujobert, Pierre ;

Salles, Gilles .

NATURE REVIEWS CANCER, 2018, 18 (04) :224-239

[30] Follicular Lymphoma Cells Induce Changes in T-Cell Gene Expression and Function: Potential Impact on Survival and Risk of Transformation [J].

Kiaii, Shahryar ;

Clear, Andrew J. ;

Ramsay, Alan G. ;

Davies, Derek ;

Sangaralingam, Ajanthah ;

Lee, Abigail ;

Calaminici, Maria ;

Neuberg, Donna S. ;

Gribben, John G. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (21) :2654-+

← 1 2 3 4 5 6 7 →